The synthetic form of progesterone most commonly prescribed for postmenopausal hormone replacement therapy in the United States may erase the therapy's intended heart benefits. Reactivity-based coronary vasospasm independent of atherosclerosis in rhesus monkeys.
Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm.
Williams, J.K., and M.R. Adams. Estrogens, progestins and coronary artery reactivity. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Adler, T. 1994. New success with heart disease drugs.